Vorinostat, Carboplatin and Gemcitabine Plus Vorinostat Maintenance in Women With Recurrent, Platinum-Sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

This study has been terminated.
(Terminated due to unacceptable toxicity)
Brigham and Women's Hospital
Massachusetts General Hospital
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Ursula A. Matulonis, MD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
First received: May 26, 2009
Last updated: June 12, 2015
Last verified: June 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: June 2015
  Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)